AptarGroup (ATR) Q1 FY26 earnings call

The first quarter unfolded largely as expected, with reported sales growth benefiting from currency, but core sales were flat due to anticipated emergency medicine destocking. While key areas like injectables and prestige fragrance performed well, the company faced margin pressure from product mix and operational challenges in beauty and closures. Management expects sequential improvements and solid growth across segments in Q2, excluding the emergency medicine impact.